GRAIL (NASDAQ:GRAL) Trading Down 7.6% – Should You Sell?

GRAIL, Inc. (NASDAQ:GRAL)’s stock price traded down 7.6% during mid-day trading on Friday . The stock traded as low as $69.75 and last traded at $70.0250. Approximately 125,960 shares changed hands during trading, a decline of 87% from the average daily volume of 988,306 shares. The stock had previously closed at $75.79.

More GRAIL News

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest batch of articles.
• Neutral Sentiment: Several law firms, including Rosen, Berger Montague, Schall, Faruqi & Faruqi, Levi & Korsinsky, and others, are reminding investors about the ongoing class action and the August 4, 2026 lead plaintiff deadline, keeping the legal issue in focus. Article Title
• Neutral Sentiment: Robbins LLP and other firms are urging stockholders who bought shares during the alleged class period to contact them for information about joining the lawsuit, suggesting the case is still actively being marketed to affected investors. Article Title
• Negative Sentiment: The core negative takeaway is that the lawsuit centers on the February 20, 2026 trial update, which reportedly erased more than $2.2 billion in market value and is now being framed as securities fraud, a headline that can weigh on investor sentiment. Article Title

Analyst Ratings Changes

Several analysts have weighed in on GRAL shares. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Piper Sandler upped their price objective on shares of GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. Guggenheim lowered their target price on shares of GRAIL from $130.00 to $75.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Robert W. Baird set a $70.00 target price on shares of GRAIL in a research report on Wednesday, May 6th. Finally, The Goldman Sachs Group initiated coverage on shares of GRAIL in a research note on Friday, June 5th. They issued a “neutral” rating and a $60.00 price target for the company. Four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, GRAIL presently has a consensus rating of “Hold” and a consensus price target of $67.00.

GRAIL Stock Performance

The company has a market cap of $3.09 billion, a P/E ratio of -6.94 and a beta of 3.22. The stock has a 50-day moving average of $64.29 and a two-hundred day moving average of $70.02.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, topping the consensus estimate of ($2.76) by $0.47. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. The firm had revenue of $40.78 million for the quarter, compared to the consensus estimate of $39.16 million. As a group, sell-side analysts forecast that GRAIL, Inc. will post -10.91 EPS for the current fiscal year.

Insider Activity at GRAIL

In other news, insider Andrew John Partridge sold 1,491 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the sale, the insider owned 163,738 shares of the company’s stock, valued at approximately $10,001,117.04. The trade was a 0.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.83% of the company’s stock.

Institutional Investors Weigh In On GRAIL

Several institutional investors have recently added to or reduced their stakes in the company. Fifth Third Bancorp grew its stake in shares of GRAIL by 15,733.3% in the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock worth $25,000 after purchasing an additional 472 shares during the last quarter. N.E.W. Advisory Services LLC bought a new position in GRAIL in the 4th quarter worth $26,000. Comerica Bank boosted its stake in shares of GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in GRAIL in the fourth quarter worth about $28,000. Finally, Geneos Wealth Management Inc. grew its holdings in shares of GRAIL by 160.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock worth $30,000 after acquiring an additional 360 shares during the period.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.